Mitsubishi UFJ Asset Management Co. Ltd. Acquires Shares of 148,853 Revvity Inc. $RVTY

Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in Revvity Inc. (NYSE:RVTY) in the second quarter, HoldingsChannel.com reports. The fund acquired 148,853 shares of the company’s stock, valued at approximately $16,561,000.

Several other hedge funds have also modified their holdings of RVTY. Ascentis Independent Advisors purchased a new position in shares of Revvity in the 1st quarter valued at about $29,000. CYBER HORNET ETFs LLC purchased a new position in Revvity during the second quarter worth approximately $32,000. MUFG Securities EMEA plc purchased a new position in Revvity during the second quarter worth approximately $34,000. SJS Investment Consulting Inc. grew its holdings in Revvity by 5,210.0% in the first quarter. SJS Investment Consulting Inc. now owns 531 shares of the company’s stock valued at $47,000 after purchasing an additional 521 shares during the period. Finally, Headlands Technologies LLC acquired a new stake in Revvity in the second quarter valued at approximately $49,000. 86.65% of the stock is owned by hedge funds and other institutional investors.

Revvity Stock Performance

NYSE RVTY opened at $124.02 on Friday. The stock’s fifty day moving average is $110.94 and its two-hundred day moving average is $100.20. The firm has a market capitalization of $13.84 billion, a P/E ratio of 59.06, a price-to-earnings-growth ratio of 2.18 and a beta of 1.07. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.50 and a current ratio of 1.80. Revvity Inc. has a fifty-two week low of $81.22 and a fifty-two week high of $124.49.

Revvity (NYSE:RVTY) last issued its earnings results on Tuesday, August 4th. The company reported $1.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.21 by $0.20. Revvity had a return on equity of 8.34% and a net margin of 8.16%.The business had revenue of $729.69 million during the quarter, compared to the consensus estimate of $702.96 million. During the same period last year, the company earned $1.18 EPS. The company’s revenue for the quarter was down 1.3% on a year-over-year basis. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. On average, research analysts anticipate that Revvity Inc. will post 5.36 earnings per share for the current year.

Revvity Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 13th. Investors of record on Friday, October 23rd will be given a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a yield of 0.2%. The ex-dividend date is Friday, October 23rd. Revvity’s dividend payout ratio (DPR) is presently 13.33%.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. JPMorgan Chase & Co. reduced their price target on shares of Revvity from $96.00 to $90.00 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. TD Cowen reiterated a “buy” rating on shares of Revvity in a report on Wednesday, July 15th. Wall Street Zen lowered Revvity from a “buy” rating to a “hold” rating in a research note on Sunday, August 16th. Weiss Ratings upgraded Revvity from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, July 30th. Finally, Wolfe Research assumed coverage on Revvity in a research note on Tuesday, June 2nd. They issued a “peer perform” rating on the stock. Three investment analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the company. According to MarketBeat.com, Revvity presently has a consensus rating of “Hold” and a consensus target price of $108.36.

Revvity Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.